Iovance Biotherapeutics Inc. appointed Timothy Morris to be CFO, effective Aug. 14.
Morris most recently served as CFO and head of business development of AcelRx Pharmaceuticals Inc.
Discover more about S&P Global’s offerings
Iovance Biotherapeutics names CFO
Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Essential IR Insights Newsletter - February 2023
Iovance Biotherapeutics Inc. appointed Timothy Morris to be CFO, effective Aug. 14.
Morris most recently served as CFO and head of business development of AcelRx Pharmaceuticals Inc.